Telix Pharmaceuticals (NASDAQ:TLX) Stock Price Up 8.7% – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX) rose 8.7% during trading on Thursday . The stock traded as high as $9.43 and last traded at $9.5350. Approximately 77,501 shares traded hands during trading, a decline of 64% from the average daily volume of 212,775 shares. The stock had previously closed at $8.77.

Analyst Upgrades and Downgrades

TLX has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Monday, April 13th. Citigroup boosted their price objective on Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a report on Tuesday, February 24th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Wall Street Zen upgraded Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Finally, Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.13.

Telix Pharmaceuticals Stock Performance

The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The company has a 50-day moving average of $10.05 and a 200-day moving average of $8.71.

Insiders Place Their Bets

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch acquired 34,500 shares of the business’s stock in a transaction on Tuesday, April 28th. The shares were acquired at an average price of $14.48 per share, with a total value of $499,560.00. Following the completion of the transaction, the chief executive officer owned 20,709,500 shares in the company, valued at approximately $299,873,560. This trade represents a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its position in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares during the last quarter. Lazard Asset Management LLC boosted its position in Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares during the last quarter. XY Capital Ltd purchased a new position in Telix Pharmaceuticals in the first quarter worth $120,000. Private Advisor Group LLC boosted its position in Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after purchasing an additional 128,070 shares during the last quarter. Finally, Vident Advisory LLC purchased a new position in Telix Pharmaceuticals in the fourth quarter worth $204,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.